These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 33065780)
1. Effect of evolocumab on the progression and stability of atherosclerotic plaques as evaluated by grayscale and iMAP-IVUS. Kong Q; Liu M; Li Y; Zhu Q; Su G Ann Palliat Med; 2020 Sep; 9(5):3078-3088. PubMed ID: 33065780 [TBL] [Abstract][Full Text] [Related]
2. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis. Liang D; Li C; Tu Y; Li Z; Zhang M Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013 [TBL] [Abstract][Full Text] [Related]
3. Effect of Evolocumab on Coronary Plaque Composition. Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824 [TBL] [Abstract][Full Text] [Related]
4. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841 [TBL] [Abstract][Full Text] [Related]
5. THE EFFECT OF EVOLOCUMAB ALONE AND IN COMBINATION WITH ATORVASTATIN ON LIPID PROFILE. Saud AH; Ali NAJ; Gali FY; Hadi NR Wiad Lek; 2021; 74(12):3184-3187. PubMed ID: 35058387 [TBL] [Abstract][Full Text] [Related]
6. The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression. Saud A; Ali N; Gali F; Qassam H; Hadi NR J Med Life; 2023 May; 16(5):759-765. PubMed ID: 37520489 [TBL] [Abstract][Full Text] [Related]
7. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344 [TBL] [Abstract][Full Text] [Related]
8. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172 [TBL] [Abstract][Full Text] [Related]
9. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA; N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979 [TBL] [Abstract][Full Text] [Related]
10. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337 [TBL] [Abstract][Full Text] [Related]